Skip to content

Emergent BioSolutions Inc.

EBS NYSE SEC CIK 1367644

Follow Emergent BioSolutions Weekly email: filings, results, news

News

9 stories filed under Emergent BioSolutions, grouped into ongoing threads

Call

Thread · 3 stories

Emergent Biosolutions Q2 Earnings Call Highlights

Earnings 47 d ago

Emergent BioSolutions Inc. (EBS) Q2 2026 Earnings Call Transcript

Earnings 48 d ago

Emergent BioSolutions Inc. 2026 Q2 - Results - Earnings Call Presentation

Earnings 50 d ago

More coverage

Emergent BioSolutions - Tough 2026 Outlook Warrant Rating Downgrade

Markets 18 d ago

Emergent BioSolutions repurchases $75 million in senior notes

Markets 21 d ago

Emergent BioSolutions Awarded Government of Canada Standing Offer for NARCAN® Nasal Spray

Markets 24 d ago

Emergent BioSolutions Reinforces Commitment to Opioid Overdose Education and Preparedness on International Overdose Awareness Day

Markets 24 d ago also on TAAG

U.S. FDA Accepts Teva’s New Drug Application (NDA) and Grants Priority Review for Ecopipam, a First-in-Class Investigational Therapy for Pediatric Patients with Tourette Syndrome

Markets 36 d ago

S&P downgrades Emergent BioSolutions outlook on competition

Markets 37 d ago

Next results

NOV5

Q3 2026 results

Thursday · estimated from the filing cadence

Profile

Headquarters: GAITHERSBURG, MD, United States
Sector: Healthcare
Industry: Pharmaceutical Preparations

Peers

Where this page comes from

Profile · SEC EDGAR

Next results · estimated from the filing cadence (SEC EDGAR)

News · 9 stories clustered from the RSS aggregator